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infections in these patients requires early diagnosis, differentiation
from other conditions, and the ability to monitor the infection
after treatment. We have developed a real time quantitative PCR
assay for BKV and hereby present data to support its’ clinical
utility. Methods: The forward and reverse primers for our PCR
assay were designed to amplify a conserved region of Agno and
VP-1 genes. Additionally, to monitor the PCR product during the
ampliﬁcation, we designed a TaqMan probe that is complimentary
to the internal region of the ampliﬁed product. The assay has
undergone clinical validation and proﬁciency testing. We tested
our assay on 259 clinical specimens (129 blood, 124 urine, 3 ﬂuid,
1 tissue sample) from 62 BMT patients with hemorrhagic cystitis
for BKV load determination. Results: BKV was detected in 41
patients of the total 62 patients tested. Of the 129 blood samples,
68 tested positive for BKV, the result range is 400-1.9107copies/
ml. Similarly, of the 124 urine samples, 100 tested positive, the
result range is 100-109copies/ml. One BKV-positive patient fol-
lowed serially for hemorrhagic cystitis had persistently high levels
of BK virus in the urine (1.2-1.3109copies/ml) despite clearing
from the blood (with an initial viral load of 1.4106copies/ml).
This 15-year old male with unrelated donor marrow transplant for
treatment of paroxysmal nocturnal hemoglobinuria, had a stormy
post transplant course complicated by severe hemmorhagic cystitis,
aGVHD, and aspergillus and pseudomonas sinusitis. At 140 days
post transplant, he developed pancytopenia and sinopulmonary
disease with a mild ﬂair of hemmorhagic cystitis. No CMV, EBV
or adenovirus could be detected in this patient. However, on
further testing, BKV was found in bone marrow (6.5104 copies/
ml), tracheal aspirate (6.1104 copies/ml), and lung tissue (16
copies/cell) supporting progressive dissemination of the BK virus.
Conclusions: This assay can provide a sensitive, speciﬁc, reliable
and rapid method for diagnosis of life-threatening BKV infection
in BMT patients and would be useful in guiding as well as moni-
toring the response to speciﬁc therapy.
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Introduction: Fungal infections cause signiﬁcant morbidity and
mortality in bone marrow transplants. Despite medical advances, it
is estimated that up to 30% of cases of fungal infections may
remain undiagnosed and untreated at death. Thus, management of
serious fungal infections in these patients requires early diagnosis,
differentiation from other conditions and the ability to monitor the
infection after treatment. Unfortunately, rapid, accurate, sensitive,
and quantitative diagnostics for fungal infections do not exist at this
time. We investigated if quantitative real time PCR technology can
be applied to fungal infections to produce a diagnostic test that can
provide sensitive, accurate, and early detection. Methods: For
fungal genomic DNA isolation, we evaluated 3 commercially avail-
able kits: QIAamp Tissue Kit (Qiagen Inc), MagNA Pure Kit
(Roche Diagnostics), and E. Z. N. A. Fungal DNA Kit (Omega
Bio-tek). We selected 15 different published primer sets and ap-
plied them to both traditional and real time PCR. These primers
were reportedly designed for pan-fungal (PF), pan-Aspergillus (PA)
and pan-Candida (PC) categories. This assay was studied to eval-
uate ampliﬁcation of various Candida (n  4), Aspergillus sp (n  5)
and yeast DNA, both in pure form, in spiked blood, and in a
clinical urine sample. Results: Of the 3 commercially available kits
we evaluated for fungal genomic DNA isolation, our results
showed that the MagNA Pure Kit works better than other kits.
Eleven of the 15 published primer sets could detect fungal ge-
nomes by traditional PCR assay or by the real time assay using
non-speciﬁc SYBR Green dye. Four primer sets (1 PA, 1 PC, 2 PF)
failed to amplify several key fungal strains. Besides, we also iden-
tiﬁed cross ampliﬁcation by several PA and PC primers sets (i.e. PA
primer sets ampliﬁed Candida genomes and vice versa). Conclu-
sion: Developing a single molecular diagnostic assay that can
detect thousands of fungal species is a major challenge. In order to
develop such an assay, we ﬁrst evaluated the published primers.
Our results showed that the majority of them cross-react with
different fungal genera, while several failed to amplify key fungal
genomes—thus giving rise to both false positive and false negative
results. Currently, we are further investigating the development of
fungal assays based on TaqMan and LUX (Light Upon eXtension)
chemistry that would be rapid, sensitive, speciﬁc, and accurate.
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Introduction: Adenovirus (AdV) can cause signiﬁcant morbidity
and mortality in BMT patients. Management of serious AdV in-
fections in these patients requires early diagnosis, differentiation
from other conditions, and the ability to monitor the infection
after treatment. We have developed a quantitative PCR assay for
AdV and hereby present data to support its clinical utility. Meth-
ods: We utilized the real time PCR technique (TaqMan) to quan-
tify AdV DNA in clinical specimens based on the conserved region
of the hexon gene. Additionally, we designed a minor groove-
binding (MGB) label to allow the use of a small oligonucleotide
probe to detect several AdV serotypes. Results: The assay detected
13 of 13 different AdV serotypes. We screened 154 clinical spec-
imens and identiﬁed 5 positive patients. Four positive patients were
monitored serially. Pt #1, with acute GVHD, following bone
marrow transplantation presented with fever, diarrhea and pro-
gressive liver dysfunction. The blood PCR for AdV was positive
and the viral load increased as the liver function worsened (from
5103 copies/ml with AST of 81 to 11103 copies/ml with AST of
198 and progressing to 1.9106 copies/ml with AST of 1061). The
patient died following the peak AdV load of 1.4108copies/ml.
The patient’s liver biopsy by EM found to have particles suggestive
of AdV. Pt #2, with chronic GVHD, on immunosuppressive ther-
apy presented with an acute febrile illness and was found to have an
initial blood AdV load of 5104 copies/ml. He promptly improved
after treatment with high dose IV IgG, with the viral load dropping
to 200 copies/ml. A few weeks later, after a 2nd increase in viral
load (6,200 copies/ml), he was again treated with IV IgG followed
by a decrease in viral load to 200 copies/ml. Four weeks later, after
another dose of IV IgG, the AdV load became undetectable. Pt#3
developed AdV load up to 1.6106copies/ml, did not respond to
IV IgG, but responded promptly to cidofovir with rapid drop in
AdV load and clinical improvement. Unfortunately, Pt#4 with low
AdV load 2103 copies/ml, treated with IV IgG without any
response, then rapidly developed hepatitis and died with very high
AdV load. Conclusions: Use of MGB probe allowed the detection
of multiple AdV serotypes with limited sequence homology. This
assay can provide a rapid method for diagnosis of life-threatening
AdV infection in BMT patients and would be useful in guiding as
well as monitoring the response to speciﬁc therapy.
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VIDEO VISUALIZATION OF THE SMALL BOWEL AIDS IN THE EVALUA-
TION OF INTESTINAL GRAFT VERSUS HOST DISEASE (GVHD)
Morris, J.D., Klooster, M., Condon, D., Zupan, C., Runge, S., Morris,
C.L. Loma Linda University Medical Center, Loma Linda, CA
Endoscopic evaluation for gastrointestinal graft versus host dis-
ease (GvHD) following allogeneic bone marrow transplant (BMT)
is of limited value for detection of distal small bowel disease. Video
visualization was used to evaluate the distal small bowel of a 9 year
old with severe gastrointestinal GvHD following a matched sibling
donor allogeneic BMT. The patient developed severe intestinal
GvHD 30 days after BMT characterized by secretory diarrhea
(1500 cc stool/day) nausea and vomiting. Endoscopy showed ul-
cerations of the duodenum and colon, and biopsies showed histo-
logical ﬁndings of GvHD. The patient was treated with tacrolimus,
methylprednisolone, and ATG. Stool output decreased to 500cc/
day after 3 weeks, but the nausea and abdominal pain persisted.
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